- de Sousa E Melo Felipe, Wang Xin, Jansen Marnix, Fessler Evelyn, Trinh Anne, de Rooij Laura P. M. H., de Jong Joan H., de Boer Onno J., van Leersum Ronald, Bijlsma Maarten F., Rodermond Hans, van der Heijden Maartje, van Noesel Carel J. M., Tuynman Jurriaan B., Dekker Evelien, Markowetz Florian, Medema Jan Paul, Vermeulen Louis Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions Nature medicine 2013;19 (5):614-618 [PubMed]
- Guinney Justin, Dienstmann Rodrigo, Wang Xin, de Reyniès Aurélien, Schlicker Andreas, Soneson Charlotte, Marisa Laetitia, Roepman Paul, Nyamundanda Gift, Angelino Paolo, Bot Brian M., Morris Jeffrey S., Simon Iris M., Gerster Sarah, Fessler Evelyn, de Sousa E Melo Felipe, Missiaglia Edoardo, Ramay Hena, Barras David, Homicsko Krisztian, Maru Dipen, Manyam Ganiraju C., Broom Bradley, Boige Valerie, Perez-Villamil Beatriz, Laderas Ted, Salazar Ramon, Gray Joe W., Hanahan Douglas, Tabernero Josep, Bernards Rene, Friend Stephen H., Laurent-Puig Pierre, Medema Jan Paul, Sadanandam Anguraj, Wessels Lodewyk, Delorenzi Mauro, Kopetz Scott, Vermeulen Louis, Tejpar Sabine The consensus molecular subtypes of colorectal cancer Nature medicine 2015;21 (11):1350-1356 [PubMed]
- Vermeulen Louis, Morrissey Edward, van der Heijden Maartje, Nicholson Anna M., Sottoriva Andrea, Buczacki Simon, Kemp Richard, Tavaré Simon, Winton Douglas J. Defining Stem Cell Dynamics in Models of Intestinal Tumor Initiation Science 2013;342 (6161):995-998 [PubMed]
- Medema Jan Paul, Vermeulen Louis Microenvironmental regulation of stem cells in intestinal homeostasis and cancer Nature 2011;474 (7351):318-326 [PubMed]
- Punt Cornelis J. A., Koopman Miriam, Vermeulen Louis From tumour heterogeneity to advances in precision treatment of colorectal cancer Nature reviews. Clinical oncology 2017;14 (4):235-246 [PubMed]
2013 - present Principal Investigator at the Center for Experimental Molecular Medicine, Academic Medical Center, Amsterdam.
2011-2013 Research Fellow at the Cancer Research UK – Cambridge Institute, University of Cambridge, Cambridge, UK.
2011-2013 Fellow of Wolfson College, Cambridge University.
2010-2012 Post-doc at the Laboratory for Experimental Oncology and Radiobiology, Center for Experimental Molecular Medicine, Academic Medical Center, Amsterdam.
2006-2010 PhD student in Experimental oncology. Academic Medical Center, Amsterdam.
2012 MD degree (cum laude), Academic Medical Center, University of Amsterdam.
2010 PhD degree (cum laude), Academic Medical Center, University of Amsterdam. Thesis: “Cancer Stem Cells – a numbers game?”.
Awards, honours, prizes, career development grants etc.
- European Research Council (ERC) Starting Grant , 2014
- Maag Lever Darm Stichting (MLDS) Career Development Grant, 2014
- MD degree, cum laude, 2012
- Junior Research Fellowship, Wolfson College, Cambridge, UK, 2011
- Dutch Cancer Society Fellowship/KWF Fellowship, 2011
- AMC Graduate School – Excellent Thesis Award 2010
- PhD degree, cum laude, 2010
- AMC Graduate School – Young Scientist Publication Award 2008, 1st prize
Prof. L. Vermeulen MD PhD (Molecular Oncology)
Louis Vermeulen MD PhD is a group leader/principal investigator within the Center for Experimental Molecular Medicine (CEMM), Laboratory for Experimental Oncology and Radiobiology (LEXOR) at the Academic Medical Center (AMC), Amsterdam. Louis Vermeulen studied medicine and obtained his PhD at the AMC, and afterwards worked as a research fellow at the University of Cambridge, UK. His group uses quantitative approaches in combination with state of the art in vitro and in vivo models to study the biology of intestinal cancers in order to improve tumor classification and therapies.
In particular his research focuses on:
1. Stem cell dynamics in developing and established cancers
Stem cells are essential for the homeostasis of most adult human tissues. Previously we identified stem-like cells that fuel the growth and progression of cancers. We elucidated how oncogenic mutations alter the population dynamics during tumorigenesis. In addition we defined microenvironmental factors that regulate stem cell function in cancers. We have now developed marker free tracing approaches to study the functional behavior of stem-like cells in both pre-neoplastic lesions and human cancer tissue. We use these tools to improve chemopreventive strategies and to develop novel, and more effective therapies.
2. Molecular cancer subtypes
Colorectal cancer is a highly heterogeneous disease. Intriguingly, the genetic features of cancers only explain part of this. Recently we have developed gene expression based classifications that identify colorectal cancer subtypes with radically different molecular features and clinical properties, including their response to commonly used targeted agents. We now develop improved and clinically applicable classification assays, aim to elucidate the molecular drivers of the unique properties of each subtype, and evaluate subtype-specific therapeutic interventions.
Louis Vermeulen is supported by several personal grants, including an ERC starting grant, a VIDI grant from the Dutch Science Organization (NOW/ZonMw), and a career development grant of the Dutch Digestive Foundation (MLDS).
V. Kakkar PhD
K.J. Lenos PhD
N. Leveille PhD
D.M. Miedema PhD
J. Romero Ros PhD
S. Simmini PhD
J.F. Linnekamp MD
N.E. de Groot
K. El Makrini BEng
L.E. Nijman BEng
A. van Oort BEng
Prof. J.P. Medema PhD (Cell death induction and resistance in tumor cells)
Prof. C.J.A. Punt MD PhD (Clinical and translational research in gastrointestinal cancer, with focus on colorectal cancer)
- AMC (Vrijgesteld)
- BAYER B.V.
- Europese Unie
- Innovatiefonds Zorgverzekeraars
- KWF Kankerbestrijding
- Life Sciences Health TKI
- Maurits en Anna de Kock Stichting
- Servier Nederland Farma B.V.
- Stichting Oncode Institute
- The New York Stem Cell Foundation (NYSF)